Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$9.00 USD
+0.29 (3.33%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $9.01 +0.01 (0.11%) 4:46 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 34% (85 out of 251)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.58 | 9.99 |
Current Quarter Estimate | -0.23 | -1.17 | 61.00 |
Year Ago Quarter Estimate | -0.51 | -0.06 | 54.84 |
Next Quarter Estimate | -5.68 | -1.92 | 63.00 |
Next Year Estimate | -0.97 | 12.59 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -13.73 | 19.70 | 15.67 |
Next Year | 16.38 | 15.80 | 11.34 |
Last 5 Years | NA | 7.90 | 8.10 |
Next 5 Years | 4.40 | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -1.44 |
Price/Book (MRQ) | 3.57 | 1.54 |
Price/Cash Flow (MRFY) | NA | 9.03 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -226.46% | -61.35% |
Return on Equity (TTM) | -52.75% | -59.40% |
Debt to Equity (MRQ) | 0.18 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.